Voriconazole induced lupus. A case report and brief review
DOI:
https://doi.org/10.66344/jpad.29.1.2019.1324Keywords:
Variconazole, lupus, mycetomaAbstract
A 50-year old male developed lupus erythematosus after taking voriconazole for the treatment of mycetomaReferences
Lass-Flörl C. Triazole Antifungal Agents in Invasive Fungal Infections. Drugs 2011; 71(18): 2405-2419.
Keane M. Rare diseases bullet 7: Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000; 55(2): 159-166.
Hoffman b. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Archives of Dermatology 1945; 51(3): 190.
Johnson L, Kauffman C. Voriconazole: A New Triazole Antifungal Agent. Clinical Infectious Diseases 2003; 36(5): 630-37.
Denning D, Griffiths C. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clinical and Experimental Dermatology 2001; 26(8): 648-653.
Marzano A, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009; 18(11): 935-940.
Tolland J, McKeown P, Corbett J. Voriconazole-induced pseudoporphyria. Photodermatology, Photoimmunology & Photomedicine 2007; 23(1): 29-31.
Racette A, Roenigk H, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 2005; 52(5): S81-S85.
Pretel M, Marquès L, España A. Drug-Induced Lupus Erythematosus. Actas Dermo-Sifiliográficas (English Edition) 2014; 105(1): 18-30.
Rubin R. Etiology and mechanisms of drug-induced lupus. Current Opinion in Rheumatology. 1999; 11(5): 357-363.
Vasoo S. Drug-induced lupus: an update. Lupus. 2006; 15(11): 757-761.
Marzano A, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J of Dermatol. 2011; 165(2): 335-341.
Cozzani E, Drosera M, Gasparini G, Parodi A. Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects. Autoimmune Diseases. 2014; 2014: 1-13.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.